Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia

@article{Frnberg2007AsenapineAN,
  title={Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia},
  author={Olivia Fr{\aa}nberg and Charlotte Wiker and Monica Marcus and {\AA}sa Konradsson and Kent E Jardemark and Bj{\"o}rn Schilstr{\"o}m and Mohammed Abdul Shahid and Erik H. F. Wong and Torgny H. Svensson},
  journal={Psychopharmacology},
  year={2007},
  volume={196},
  pages={417-429}
}
Asenapine is a novel psychopharmacologic agent being developed for the treatment of schizophrenia and bipolar disorder. The present study was undertaken to investigate the effects of asenapine using animal models predictive of antipsychotic efficacy (conditioned avoidance response [CAR]) and extrapyramidal side effects (EPS; catalepsy). In parallel, the effects of asenapine on regional dopamine output using in vivo microdialysis in freely moving rats, dopamine output in the core and shell… CONTINUE READING